Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Rating) Director John B. Bode purchased 10,000 shares of Zevra Therapeutics stock in a transaction that occurred on Thursday, May 18th. The shares were bought at an average cost of $5.04 per share, for a total transaction of $50,400.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $50,400. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Zevra Therapeutics Stock Performance
NASDAQ ZVRA opened at $5.40 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.68 and a quick ratio of 7.93. The firm has a fifty day moving average of $5.29. Zevra Therapeutics, Inc. has a twelve month low of $4.03 and a twelve month high of $6.92.
Zevra Therapeutics (NASDAQ:ZVRA – Get Rating) last announced its quarterly earnings results on Tuesday, March 7th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). Zevra Therapeutics had a negative net margin of 548.93% and a negative return on equity of 38.58%. The business had revenue of $2.32 million during the quarter, compared to the consensus estimate of $3.00 million. Research analysts predict that Zevra Therapeutics, Inc. will post -1.47 EPS for the current year.
Analyst Ratings Changes
Zevra Therapeutics Company Profile
Zevra Therapeutics, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.
- Get a free copy of the StockNews.com research report on Zevra Therapeutics (ZVRA)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.